Table 2.
Tumor characteristics and treatments in the different etiologies of HCC (n = 145)
| HBV (38) | HCV (60) | NAFLD (47) | P value | |
|---|---|---|---|---|
| Within Milan (%) | 31 (82) | 51 (85) | 42 (89) | 0.592 |
| Within UCSF (%) | 31 (82) | 57 (95) | 44 (94) | 0.060 |
| Median first tumor size (cm) (IQR) | 2.8 (1.6–4.3) | 2.5 (1.9–3.6) | 2.3 (1.7–3.2) | 0.619 |
| Median AFP at presentation (IQR) | 7.7 (3.7–124) | 32.8 (11.2–149) | 6.1 (3.9–15) | < 0.0001 |
| Most definitive therapy, n (%) | ||||
| OLT | 6 (16) | 13 (22) | 20 (42) | 0.0146 |
| Resection | 10 (26) | 6 (10) | 1 (2) | |
| RFA | 9 (24) | 15 (25) | 14 (30) | |
| TACE/Y-90 | 7 (18) | 9 (15) | 2 (4) | |
| PEI | 0 (0) | 1 (2) | 0 (0) | |
| Chemotherapy | 3 (8) | 3 (5) | 3 (6) | |
| Supportive | 3 (8) | 13 (22) | 5 (11) | |
| Previous treatment prior to most definitive, n (%) | ||||
| RFA prior to OLT | 4 (11) | 9 (15) | 19 (40) | - |
| TACE prior to OLT | 8 (21) | 9 (15) | 16 (34) | |
| Others | 5 (14) | 7 (12) | 7 (15) |
IQR: Interquartile range; AFP: alpha-fetoprotein; RFA: radiofrequency ablation; TACE: trans-arterial chemoembolization; OLT: orthotopic liver transplantation.